Ocular Therapeutix (OCUL)

Executive Summary

Ocular Therapeutix (NASDAQ: OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using its proprietary bioresorbable hydrogel platform for sustained drug delivery. Its most advanced candidate, AXPAXLI (axitinib intravitreal implant), is under regulatory review for wet age-related macular degeneration (wet AMD), a leading cause of blindness. AXPAXLI aims to reduce treatment burden by providing sustained drug release, potentially extending dosing intervals to several months. The company also commercializes DEXTENZA, an FDA-approved intracanalicular insert for post-surgical ocular inflammation and pain, and allergic conjunctivitis, generating baseline revenue. The company's pipeline includes multiple programs in retinal diseases and anterior segment conditions, with a Phase 3 trial evaluating AXPAXLI plus aflibercept in wet AMD and another Phase 3 study for non-proliferative diabetic retinopathy (NPDR). Positive pivotal data for AXPAXLI could address a significant unmet need in wet AMD, currently treated with frequent anti-VEGF injections. Ocular Therapeutix is well-positioned to capture market share given its differentiated sustained-release technology. Key upcoming catalysts include regulatory decisions and progress in late-stage trials, which could drive substantial value.

Upcoming Catalysts (preview)

• Q3 2026FDA approval decision for AXPAXLI in wet AMD65% success
• Q4 2027Phase 3 data readout for AXPAXLI in NPDR50% success